ProtoKinetix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.06.23	Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication (Businesswire)
20.07.22	ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants (Businesswire)
14.01.22	ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only (Businesswire)
12.05.21	ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions (Businesswire)
22.04.21	ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes (Businesswire)
14.04.21	ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP® (Businesswire)
07.04.21	Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration (Businesswire)
24.11.20	Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision (Businesswire)
15.09.20	ProtoKinetix AAGP® Restores Vision in Blind Test Subjects (Businesswire)
27.08.20	Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada (Businesswire)
14.08.20	ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing (Businesswire)
13.07.20	Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada (Businesswire)
07.07.20	ProtoKinetix AAGP® Dry Eye Program Advancing (Businesswire)
06.04.20	ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease (Businesswire)
24.03.20	ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials (Businesswire)
19.03.20	ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease (Businesswire)
19.02.20	ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine (Businesswire)
11.02.20	ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine (Businesswire)
24.01.20	ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial (Businesswire)
06.01.20	ProtoKinetix AAGP® Dry Eye Therapy Testing Results (Businesswire)
19.12.19	ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed (Businesswire)
22.11.19	ProtoKinetix AAGP® Dry Eye Therapy Program Launched (Businesswire)
06.11.19	ProtoKinetix AAGP® Operational Update (Businesswire)
23.08.19	Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone (Businesswire)
09.07.19	ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC (Businesswire)
07.06.19	ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial (Businesswire)
30.05.19	ProtoKinetix First in Series of Town Hall Shareholder Meetings (Businesswire)
09.05.19	Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies (Businesswire)
07.05.19	ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity (Businesswire)
23.04.19	ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program (Businesswire)
26.02.19	ProtoKinetix Releases Third in a Series of Scientific Update Videos (Businesswire)
16.01.19	ProtoKinetix Releases Second in a Series of Scientific Update Videos (Businesswire)
19.12.18	ProtoKinetix Releases First in a Series of Scientific Update Videos (Businesswire)
28.09.18	ProtoKinetix Begins Cardiovascular Research (Businesswire)
04.09.18	ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions (Businesswire)
10.08.18	ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC (Businesswire)
13.06.18	ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company (Businesswire)
10.01.18	ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery (Businesswire)
16.11.17	The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy (Businesswire)
21.06.12	ProtoKinetix Creates Subsidiaries for AAGP™ Applications to Maximize Shareholder Value (Businesswire)
07.12.11	Italian Laboratory Expands ProtoKinetix’ Market for AAGP™ (Businesswire)
09.06.11	Cerus Corporation and Ilex Biotech LTD Initiate Distribution Agreements for the INTERCEPT Blood System in South Africa and Israel (Businesswire)
04.05.11	Celldex Reports First Quarter 2011 Financial Results (Businesswire)
14.01.10	Defeat Diabetes Foundation Co-Founder Joins ProtoKinetix’ Advisory Board (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu ProtoKinetix IncShs

Aktien Top/Flop

Meistgelesene Nachrichten